Celimmune

Bethesda, United States Founded: 2015 • Age: 11 yrs Acquired By Amgen
IL-15 monoclonal antibodies for celiac disease therapies are developed.
Request Access

About Celimmune

Celimmune is a company based in Bethesda (United States) founded in 2015 was acquired by Amgen in June 2017.. Celimmune offers products and services including Biologic Medicines and Clinical Trials Services. Celimmune operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.

  • Headquarter Bethesda, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Amgen Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Amgen

    (Jun 01, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Celimmune

Celimmune offers a comprehensive portfolio of products and services, including Biologic Medicines and Clinical Trials Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treat serious diseases using innovative biologic technologies

Optimize trials for faster medicine development

Funding Insights of Celimmune

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Celimmune

Celimmune has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Developer of pharmaceutical products for treating multiple diseases
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Celimmune

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Celimmune

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Celimmune Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Celimmune

Celimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Therapies for immunological and neurological disorders are developed.
domain founded_year HQ Location
Plasma-derived therapies are developed to treat multiple diseases.
domain founded_year HQ Location
Small molecule protein degraders are developed for various disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Developer of novel protein-based therapeutics using machine learning and biological engineering
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Celimmune

Frequently Asked Questions about Celimmune

When was Celimmune founded?

Celimmune was founded in 2015.

Where is Celimmune located?

Celimmune is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.

What does Celimmune do?

Celimmune was founded in 2015 in Bethesda, United States, as a clinical-stage biotechnology firm. Focus is placed on therapies for celiac disease and other immune disorders, utilizing a rapid clinical development approach. The lead candidate, AMG 714an anti-IL-15 monoclonal antibody licensed from Amgenis evaluated in phase-2 trials for non-responsive and refractory celiac disease. Development also includes iVYLISA GIP, a gluten immunoassay for diet management and clinical trial support.

Who are the top competitors of Celimmune?

Celimmune's top competitors include argenx, BioNTech and Generate Biomedicines.

What products or services does Celimmune offer?

Celimmune offers Biologic Medicines and Clinical Trials Services.

Who are Celimmune's investors?

Celimmune has 1 investor. Key investors include Amgen.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available